Lysophosphatidic acid acyltransferase β (LPAATβ) promotes the tumor growth of human osteosarcoma

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Rastegar, Farbod ^a   Gao, Jian Li ^a,b   Shenaq, Deana ^a   Luo, Qing ^a,c   Shi, Qiong ^a,d   Kim, Stephanie H ^a   Jiang, Wei ^a   Wagner, Eric R ^a   Huang, Enyi ^a,e   Gao, Yanhong ^a,f   Shen, Jikun ^a   Yang, Ke ^a,g   He, Bai Cheng ^a,d   Chen, Liang ^a,d   Zuo, Guo Wei ^a,d   Luo, Jinyong ^a,d   Luo, Xiaoji ^a,d   Bi, Yang ^a,c   Liu, Xing ^a,c   Li, Mi ^a,c   Hu, Ning ^a,d   Wang, Linyuan ^a   Luther, Gaurav ^a   Luu, Hue H ^a   Haydon, Rex C ^a   He, Tong Chuan ^a,b,c   more..

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e CHONGQING UNIVERSITY   (China)

^f XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACYLGLYCEROPHOSPHATE ACYLTRANSFERASE; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE BETA; UNCLASSIFIED DRUG; 2 ACYLGLYCEROPHOSPHATE ACYLTRANSFERASE; 2-ACYLGLYCEROPHOSPHATE ACYLTRANSFERASE; ACYLTRANSFERASE; CRYSTAL VIOLET; LIPID; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TUMOR GROWTH; TUMOR PROMOTION; TUMOR XENOGRAFT; BONE TUMOR; CELL SURVIVAL; CHEMISTRY; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOVIRIDAE;

ACYLTRANSFERASES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENTIAN VIOLET; HUMANS; LIPIDS; NEOPLASM METASTASIS; OSTEOSARCOMA; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 78649935962     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014182     Document Type: Article

References (68)

1. Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin North Am 44: 973-989.
2. Murphey MD, Robbin MR, McRae GA, Flemming DJ, Temple HT, et al. (1997) The many faces of osteosarcoma. Radiographics 17: 1205-1231.
3. Whelan JS (1997) Osteosarcoma. Eur J Cancer 33: 1611-1618; discussion 1618-1619.
4. Tang N, Song WX, Luo J, Haydon RC, He TC (2008) Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466: 2114-2130.
5. Gorlick R (2010) Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 152: 467-478.
6. Haydon RC, Luu HH, He TC (2007) Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 454: 237-246.
7. Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ, Rao BN (1999) Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 86: 1602-1608.
8. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, et al. (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606.
9. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, et al. (1994) Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12: 1849-1858.
10. Yonemoto T, Tatezaki S, Ishii T, Satoh T, Kimura H, et al. (1998) Prognosis of osteosarcoma with pulmonary metastases at initial presentation is not dismal. Clin Orthop Relat Res. pp 194-199.
11. Gordon N, Kleinerman ES (2010) The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases. Cancer Treat Res 152: 497-508.
12. Gazitt Y, Kolaparthi V, Moncada K, Thomas C, Freeman J (2009) Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol 34: 551-561.
13. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, et al. (2005) An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754.
14. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, et al. (2002) Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. International journal of cancer 102: 338-342.
15. Luo X, Chen J, Song WX, Tang N, Luo J, et al. (2008) Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Laboratory investigation; a journal of technical methods and pathology 88: 1264-1277.
16. Luu HH, Zhou L, Haydon RC, Deyrup AT, Montag AG, et al. (2005) Increased expression of S100A6 is associated with decreased metastasis and inhibition ofcell migration and anchorage independent growth in human osteosarcoma. Cancer letters 229: 135-148.
17. Feugeas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon P, et al. (1996) Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14: 467-472.
18. Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, et al. (2003) Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 9: 5442-5453.
19. Pakos EE, Kyzas PA, Ioannidis JP (2004) Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a metaanalysis. Clin Cancer Res 10: 6208-6214.
20. Sandberg AA, Bridge JA (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 145: 1-30.
21. Yokoyama R, Schneider-Stock R, Radig K, Wex T, Roessner A (1998) Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract 194: 615-621.
22. Hollenback D, Bonham L, Law L, Rossnagle E, Romero L, et al. (2006) Substrate specificity of lysophosphatidic acid acyltransferase beta - evidence from membrane and whole cell assays. J Lipid Res 47: 593-604.
23. Leung DW (2001) The structure and functions of human lysophosphatidic acid acyltransferases. Front Biosci 6: D944-953.
24. West J, Tompkins CK, Balantac N, Nudelman E, Meengs B, et al. (1997) Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells. DNA Cell Biol 16: 691-701.
25. Stamps AC, Elmore MA, Hill ME, Kelly K, Makda AA, et al. (1997) A human cDNA sequence with homology to non-mammalian lysophosphatidic acid acyltransferases. Biochem J 326(Pt 2): 455-461.
26. Eberhardt C, Gray PW, Tjoelker LW (1997) Human lysophosphatidic acid acyltransferase. cDNA cloning, expression, and localization to chromosome 9q34.3. J Biol Chem 272: 20299-20305.
27. Magre J, Delepine M, Khallouf E, Gedde-Dahl T, Jr., Van Maldergem L, et al. (2001) Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 28: 365-370.
28. Andresen BT, Rizzo MA, Shome K, Romero G (2002) The role of phosphatidic acid in the regulation of the Ras/MEK/Erk signaling cascade. FEBS Lett 531: 65-68.
29. Wang X, Devaiah SP, Zhang W, Welti R (2006) Signaling functions of phosphatidic acid. Prog Lipid Res 45: 250-278.
30. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J (2001) Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 294: 1942-1945.
31. Ghosh S, Strum JC, Sciorra VA, Daniel L, Bell RM (1996) Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol- 13-acetate-stimulated Madin-Darby canine kidney cells. J Biol Chem 271: 8472-8480.
32. Zhou Q, Deng Z, Zhu Y, Long H, Zhang S, et al. (2009) mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients' prognosis. Med Oncol.
33. Furuta E, Okuda H, Kobayashi A, Watabe K (2010) Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochimica et biophysica acta 1805: 141-152.
34. Mashima T, Seimiya H, Tsuruo T (2009) De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 100: 1369-1372.
35. Menendez JA (2010) Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. Biochimica et biophysica acta 1801: 381-391.
36. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature reviews 7: 763-777.
37. Cortes VA, Curtis DE, Sukumaran S, Shao X, Parameswara V, et al. (2009) Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell metabolism 9: 165-176.
38. Su Y, Luo X, He BC, Wang Y, Chen L, et al. (2009) Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis 26: 599-610.
39. Luu HH, Kang Q, Park JK, Si W, Luo Q, et al. (2005) An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 22: 319-329.
40. Luo X, Sharff KA, Chen J, He TC, Luu HH (2008) S100A6 expression and function in human osteosarcoma. Clin Orthop Relat Res 466: 2060-2070.
41. He BC, Chen L, Zuo GW, Zhang W, Bi Y, et al. (2010) Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16: 2235-2245.
42. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, et al. (2003) Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A: 1544-1552.
43. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, et al. (2004) Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11: 1312-1320.
44. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, et al. (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95: 2509-2514.
45. Luo J, Deng ZL, Luo X, Tang N, Song WX, et al. (2007) A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247.
46. Kang Q, Song WX, Luo Q, Tang N, Luo J, et al. (2009) A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev 18: 545-559.
47. Luo Q, Kang Q, Song WX, Luu HH, Luo X, et al. (2007) Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. Gene 395: 160-169.
48. Chen L, Jiang W, Huang J, He BC, Zuo GW, et al. (2010) Insulin-like growth factor 2 (IGF2) potentiates BMP9-induced osteogenic differentiation and bone formation. J Bone Miner Res.
49. Tang N, Song WX, Luo J, Luo X, Chen J, et al. (2009) BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. Journal of cellular and molecular medicine 13: 2448-2464.
50. He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APCregulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
51. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
52. Bi Y, Huang J, He Y, Zhu GH, Su Y, et al. (2009) Wnt antagonist SFRP3 inhibits the differentiation of mouse hepatic progenitor cells. Journal of cellular biochemistry 108: 295-303.
53. Sharff KA, Song WX, Luo X, Tang N, Luo J, et al. (2009) Hey1 basic helixloop- helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem 284: 649-659.
54. Si W, Kang Q, Luu HH, Park JK, Luo Q, et al. (2006) CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3Ainduced osteoblast differentiation of mesenchymal stem cells. Molecular and cellular biology 26: 2955-2964.
55. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, et al. (2002) Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8: 1288-1294.
56. Gieni RS, Li Y, HayGlass KT (1995) Comparison of [3H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods 187: 85-93.
57. Luo Q, Kang Q, Si W, Jiang W, Park JK, et al. (2004) Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279: 55958-55968.
58. Chou AJ, Gorlick R (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085.
59. Bonham L, Leung DW, White T, Hollenback D, Klein P, et al. (2003) Lysophosphatidic acid acyltransferase-beta: a novel target for induction of tumour cell apoptosis. Expert Opin Ther Targets 7: 643-661.
60. Niesporek S, Denkert C, Weichert W, Kobel M, Noske A, et al. (2005) Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis. Br J Cancer 92: 1729-1736.
61. Springett GM, Bonham L, Hummer A, Linkov I, Misra D, et al. (2005) Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. Cancer Res 65: 9415-9425.
62. Burton A (2006) LPAAT-beta identifies aggressive ovarian cancer. The lancet oncology 7: 893.
63. Diefenbach CS, Soslow RA, Iasonos A, Linkov I, Hedvat C, et al. (2006) Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. Cancer 107: 1511-1519.
64. Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, et al. (2005) Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferasebeta and anti-CD20 monoclonal antibodies for treatment of human non- Hodgkin's lymphomas. Clin Cancer Res 11: 4857-4866.
65. La Rosee P, Jia T, Demehri S, Hartel N, de Vries P, et al. (2006) Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clin Cancer Res 12: 6540-6546.
66. Douvas MG, Hogan KN, Ji Y, Hollenback D, Bonham L, et al. (2006) Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leukemia research 30: 1027-1036.
67. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, et al. (2003) Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res 63: 8428-8436.
68. Coon M, Ball A, Pound J, Ap S, Hollenback D, et al. (2003) Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells. Molecular cancer therapeutics 2: 1067-1078